Property-based design: optimization of drug absorption and pharmacokinetics.
about
Identification of an antimalarial synthetic trioxolane drug development candidateLead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034Minimal Pharmacophoric Elements and Fragment Hopping, an Approach Directed at Molecular Diversity and Isozyme Selectivity. Design of Selective Neuronal Nitric Oxide Synthase InhibitorsOptimization of Imidazo[4,5- b ]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid LeukemiaNovel synthetic polyamines are effective in the treatment of experimental microsporidiosis, an opportunistic AIDS-associated infectionOpen Source Bayesian Models. 1. Application to ADME/Tox and Drug Discovery DatasetsHigh-throughput metabolic stability studies in drug discovery by orthogonal acceleration time-of-flight (OATOF) with analogue-to-digital signal capture (ADC).Integration of mass spectrometry into early-phase discovery and development of central nervous system agents.The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug developmentApplication of parallel liquid chromatography/mass spectrometry for high throughput microsomal stability screening of compound libraries.Can the Internet help to meet the challenges in ADME and e-ADME?High-throughput evaluation of relative cell permeability between peptoids and peptides.Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdlesPharmaceutical profiling case study in disruptionEffects of ketoconazole on the biodistribution and metabolism of [11C]loperamide and [11C]N-desmethyl-loperamide in wild-type and P-gp knockout mice.Experimental validation of a fragment library for lead discovery using SPR biosensor technology.Physicochemical drug properties associated with in vivo toxicological outcomes: a review.Translational pharmacokinetics: challenges of an emerging approach to drug development in stroke.Rapid and efficient hydrophilicity tuning of p53/mdm2 antagonistsMedicinal chemical properties of successful central nervous system drugsVirtual screening and evaluation of Ketol-Acid Reducto-Isomerase (KARI) as a putative drug target for Aspergillosis.Guiding principles for natural product drug discovery.Comparative 3D QSAR study on β(1)-, β(2)-, and β(3)-adrenoceptor agonistsFront-loading natural-product-screening libraries for log P: background, development, and implementation.Reduction of N-hydroxylated compounds: amidoximes (N-hydroxyamidines) as pro-drugs of amidines.Predictive approaches to increase absorption of compounds during lead optimisation.A steroid-conjugated magnetic resonance probe enhances contrast in progesterone receptor expressing organs and tumors in vivo.Intestinal drug absorption and bioavailability: beyond involvement of single transport function.Prediction methods and databases within chemoinformatics: emphasis on drugs and drug candidates.The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.Characterization of plasma protein binding dissociation with online SPE-HPLC.Screening-based approaches to identify small molecules that inhibit protein-protein interactions.Strategies to improve oral drug bioavailability.The road map to oral bioavailability: an industrial perspective.Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites.P-glycoprotein transporter in drug development.Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans.Selective neuronal nitric oxide synthase inhibitors and the prevention of cerebral palsyModeling kinetics of subcellular disposition of chemicals.Drug metabolism and pharmacokinetics.
P2860
Q22061876-83729587-E1C5-4555-ACF1-D5D4069ABE81Q27489828-5A57EF8E-3EA1-4A86-B26F-C5C77EE42F77Q27649995-D78F81EC-5878-4888-AA3C-F2A5D7116B30Q27674324-267883E8-4794-4AEE-8A5D-6B97B7A86D0AQ28366812-14BE1EE9-BB63-4863-A018-1C88DC5CE0B3Q28647980-5343BD90-E330-49FA-B1FA-1588EE9B1D60Q30484521-1F861EE9-AB57-4F4E-AA73-A8CA9AB30BE2Q30780172-E8DA1B82-2754-438A-9AAE-4DE590349EE3Q30977143-A590AAA5-60E1-4939-901D-98519059F137Q31038437-9FF371AE-8A48-4D2D-A7E3-CC1E773FD0F1Q31104637-80EF243B-6D44-4008-A43C-B15FAA822786Q33336024-18643A6E-603B-4F4E-86E2-C0AAAB0DBB50Q33683206-98CEF987-3264-427F-A792-A0A8A71549F8Q33752849-C206122D-15C9-4AF6-B5A6-C22D4039ACD7Q33761780-1E4FE43F-2FFC-4D7F-BEA3-5B39BD14AAA3Q33768454-ED78D271-AC14-4BEE-95CA-2888A36C987DQ33845886-970C6497-7326-45B4-86BF-DAACCC22BCB2Q33882182-A8065A59-101C-43EC-B59D-E4D25299EBBCQ33937376-1CD883F6-5A53-4DE2-BAD5-EDD3B50C0177Q33946968-CEB3C6E0-0C95-4707-8A64-C599A12464A3Q34149028-12AC3244-306B-41AA-94E7-E467B376F2A9Q34307956-2999AE7A-E9A6-4870-AAC1-8C4AF1FD796FQ34332971-33FBF95B-7399-418A-B5CB-41E56A3D0EF2Q34663296-C09AA4F3-1478-48F6-9710-F1F954A14B29Q34819094-17650E05-42C1-4C80-A9FC-B55EFCF913FEQ34833273-9527A5E6-EC3F-488B-8499-566219413E41Q35141461-5768D84C-7304-4FEB-953A-5549CEC2B055Q35153169-BA671EF7-BA8E-4CD7-A881-501012BB07C9Q36043183-DBCAAF94-2330-4ED6-A494-A1BA11EFEB5AQ36088451-39C912B7-C470-4105-A554-E22487DB7826Q36149937-7479539E-F987-4AFF-9CEC-0D9ACDB5EF0DQ36244148-C15333BE-1FD9-40CF-8907-15468D2072B3Q36316751-AD1F152D-EC29-498B-A8FC-0FA5C7A2B78EQ36543116-E148794D-DEBC-4CA4-807C-4C11D9525358Q36583732-AB52F40F-D1A8-4FF0-BB06-4275B5CEEDAAQ36755799-765CE6D5-5EF7-4311-9AC6-CF552F2F4B23Q36909306-B1CA658F-99F5-4CA2-BA3C-6A71369FB938Q37135549-89BEDFA6-DA3F-4CE5-8981-85DE19BDBF8BQ37194304-35DE8125-354E-415E-A91B-CD9DC50F96C6Q37550548-6E7DC786-FD00-4D1E-8EF8-C3697EE535A8
P2860
Property-based design: optimization of drug absorption and pharmacokinetics.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Property-based design: optimization of drug absorption and pharmacokinetics.
@ast
Property-based design: optimization of drug absorption and pharmacokinetics.
@en
Property-based design: optimization of drug absorption and pharmacokinetics.
@nl
type
label
Property-based design: optimization of drug absorption and pharmacokinetics.
@ast
Property-based design: optimization of drug absorption and pharmacokinetics.
@en
Property-based design: optimization of drug absorption and pharmacokinetics.
@nl
prefLabel
Property-based design: optimization of drug absorption and pharmacokinetics.
@ast
Property-based design: optimization of drug absorption and pharmacokinetics.
@en
Property-based design: optimization of drug absorption and pharmacokinetics.
@nl
P2093
P356
P1476
Property-based design: optimization of drug absorption and pharmacokinetics.
@en
P2093
Beaumont K
van De Waterbeemd H
P304
P356
10.1021/JM000407E
P407
P577
2001-04-01T00:00:00Z